Navigation Links
Schwarz's New Epilepsy Drug Reduces Seizures

An experimental epilepsy drug, lacosamide, developed by U.S firm Schwarz has found to be potential in reducing the frequency of seizures in patients// not controlled by other drugs - the company said on Monday following the results of a phase 3 trial.

The results of the 485-patient study were presented at the North American Regional Epilepsy Congress. The results proved that epileptics treated with a 200-mg dose of the drug, lacosamide, had 14.4 percent fewer seizures than those given a placebo, while patients given a 400-mg dose had 15 percent fewer seizures than placebo-treated patients. Dizziness, headache and double vision, are considered to be the two major side effects of the drug, lacosamide - the company added.

"We are delighted that lacosamide has demonstrated efficacy in a very difficult-to-treat patient population," said Iris Loew-Friedrich, a member of Schwarz' executive board.

"This trial will be submitted to the regulatory agencies in both the European Union and the (United States) as part of the marketing authorization application for lacosamide as adjunctive therapy in adults with partial seizures," Loew-Friedrich added.

Around 2.3 million Americans suffer from epileptic seizures and about 30 percent of them require two or more drugs to control the seizures, said Mike Davis, product director for Schwarz Pharma, which is being acquired by Belgian pharmaceutical group UCB SA.

It is expected that the full results from a second Phase III trial of lacosamide will be announced early next year and the drug could be on the market within the next year or so depending on the regulatory issues. – added the report.


SRI
'"/>




Page: 1

Related medicine news :

1. General Anesthesia Safe For Children On Ketogenic Diet Suffering From Epilepsy
2. Researchers Scale to assess the Severity of Epilepsy in Kids
3. Epilepsy can be predicted
4. Epilepsy Drugs Can Enhance Risk of Birth Defects
5. Epilepsy Drug Helps Diabetic Nerve Damage
6. Epilepsy Drug May Relieve Chronic Headaches
7. More Complications Seen In Women With Epilepsy
8. Epilepsy Drugs Found To Lead To Bone Loss
9. Another Use For Epilepsy Drugs
10. Epilepsy Patients Could Benefit From Pacemakers
11. Early Surgery For Treatment Of Epilepsy Questioned
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2017)... ... March 27, 2017 , ... ... to the OSEHRA popHealth Community in 2014. It is the culmination ... the Developer Open Source Project Group. OSEHRA Organizational Member Zato Health co-funded the ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... announced it will co-exhibit with technology partners LG Business Solutions at ATARC ... Metro Center in Washington D.C., will provide education and examination into the mobility ...
(Date:3/27/2017)... ... March 27, 2017 , ... Adding to its ... Journal of Medicine and NEJM Journal Watch, announces the release of NEJM ... by a panel of pediatricians from leading medical centers. The content was then ...
(Date:3/27/2017)... Rock, AR (PRWEB) , ... March 27, 2017 , ... ... CMSA National Board of Directors on June 30, 2017. CMSA’s membership has elected ... In addition to our current Military Advisory position, a new VA Advisory position has ...
(Date:3/27/2017)... ... March 27, 2017 , ... Osteitis pubis may be ... groin injury, it occurs when the muscles around the pelvis become inflamed. Over ... the lower torso, as well as accompanying tenderness and weakness. Without proper intervention, ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017 The ... reach USD 16.0 billion by 2025, according to a ... prevalence of chronic diseases is anticipated to be responsible ... which thereby widens the scope for growth during the ... bariatric population, which is highly susceptible to chronic diseases, ...
(Date:3/27/2017)...  Twist Bioscience, a company accelerating science and innovation ... raised an additional $33 million. To date, Twist Bioscience ... "It is an exciting time to be leading ... to deliver industry-leading gene volume to our customers, enabling ... Leproust, Ph.D., CEO of Twist Bioscience. "We welcome the ...
(Date:3/27/2017)... , March 27, 2017   Genprex, Inc. , a ... Julien Pham , MD, the Company,s Chief Operating Officer, is ... conferences. Sachs 5th Annual Cancer BioPartnering & Investment ... New York, NY ... BioCentury 24th Annual Future Leaders in Biotech ...
Breaking Medicine Technology: